LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2

Guizhi Jia¹,²†, Yan Wang¹,²†, Chengjie Lin¹,²†, Shihui Dai¹,², Hongliang Dai¹,², Zhinan Wang¹, Luo Dai¹,², Huizhao Su¹,², Yanjie Song³,⁴, Naiwen Zhang³,⁴, Yukuan Feng³,⁴*, and Bo Tang¹,²*

Abstract

Background: Mounting evidence has suggested the essential role of long non-coding RNAs (lncRNAs) in a plethora of malignant tumors, including hepatocellular carcinoma. However, the underlying mechanisms of lncRNAs remain unidentified in HCC. The present work was aimed to explore the regulatory functions and mechanisms of LncRNA LNCAROD in HCC progression and chemotherapeutic response.

Methods: The expression of LNCAROD in HCC tissues and cell lines were detected by quantitative reverse transcription PCR (qPCR). Cancer cell proliferation, migration, invasion, and chemoresistance were evaluated by cell counting kit 8 (CCK8), colony formation, transwell, and chemosensitivity assays. Methylated RNA immunoprecipitation qPCR (MeRIP-qPCR) was used to determine N6-methyladenosine (m⁶A) modification level. RNA immunoprecipitation (RIP) and RNA pull down were applied to identify the molecular sponge role of LNCA ROD for modulation of miR-145-5p via the competing endogenous RNA (ceRNA) mechanism, as well as the interaction between LNCAROD and serine-and arginine-rich splicing factor 3 (SRSF3). The interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) and LNCAROD was also identified by RIP assay. Gain-or-loss-of-function assays were used to identify the function and underlying mechanisms of LNCAROD in HCC.

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Results: We found that LNCAROD was significantly upregulated and predicted a poorer prognosis in HCC patients. LNCAROD upregulation was maintained by increased m^6^A methylation-mediated RNA stability. LNCAROD significantly promoted HCC cell proliferation, migration, invasion, and chemoresistance both in vitro and in vivo. Furthermore, mechanistic studies revealed that pyruvate kinase isoform M2 (PKM2)-mediated glycolysis enhancement is critical for the role of LNACROD in HCC. According to bioinformatics prediction and our experimental data, LNCAROD directly binds to SRSF3 to induce PKM switching towards PKM2 and maintains PKM2 levels in HCC by acting as a ceRNA against miR-145-5p. The oncogenic effects of LNCAROD in HCC were more prominent under hypoxia than normoxia due to the upregulation of hypoxia-triggered hypoxia-inducible factor 1α.

Conclusions: In summary, our present study suggests that LNCAROD induces PKM2 upregulation via simultaneously enhancing SRSF3-mediated PKM switching to PKM2 and sponging miR-145-5p to increase PKM2 level, eventually increasing cancer cell aerobic glycolysis to participate in tumor malignancy and chemoresistance, especially under hypoxic microenvironment. This study provides a promising diagnostic marker and therapeutic target for HCC patients.

Keywords: LINC01468, Hepatocellular carcinoma, Chemosensitivity, Aerobic glycolysis, miR-145-5p

Background

Hepatocellular carcinoma (HCC) is one of the leading malignancies worldwide, representing the sixth most common cause of cancer-related deaths [1]. In 2012, approximately 745,500 deaths worldwide were associated to HCC, nearly half of which occurred in China [2]. Despite improvements in surgical procedures and chemical therapies, HCC continues to have an extremely poor prognosis, with its incidence rate approximating the death rate [3]. Particularly, HCC treatment efficiency is severely hampered by the frequent occurrence of chemoresistance, because the malignant behaviors of this highly lethal disease, including its etiology and chemoresistance mechanisms, remain poorly defined and an increased understanding of the genetic and epigenetic mechanisms underlying the initiation, development, and chemotherapeutic response of HCC is required to develop more effective therapeutic intervention strategies.

Long non-coding RNAs (lncRNAs), which are larger than 200 nucleotides, are heterogeneous transcripts with no or weak protein-coding capacity. Several studies have demonstrated that lncRNAs are involved in various pathophysiological processes, such as cell growth, apoptosis, and metastasis [4]. Moreover, lncRNAs are abnormally expressed in multiple cancers and function as pivotal tumor promoters or suppressors [5, 6]. Increasing evidence has shown that lncRNAs could regulate cell phenotypes via multiple distinct mechanisms, including genomic imprinting, chromatin modification, and RNA decay and by acting as competing endogenous RNAs (ceRNAs) or molecular sponges for miRNAs to modulate messenger RNA (mRNA) stability in both cancerous and non-cancerous tissues [7–10]. For example, lncRNA PICSAR upregulated the eukaryotic initiation factor 6 (EIF6) by functioning as a ceRNA and sponging miR-588 in HCC cells, thus causing PI3K/AKT/mTOR activation to mediate HCC cell proliferation, colony formation, cell cycle progression, and apoptosis inhibition [11]. The lncRNA ZFPM2-AS1 was overexpressed in HCC tissues and promoted HCC cell malignancy via the regulation of the ZFPM2-AS1/miR-139/GDF10 signaling axis [12]. In addition, many lncRNAs distributed in the nucleus have been implicated in the regulation of chromatin remodeling and transcription [13].

Here, we focused on LNCAROD, also called LINC01468 or Inc-MLBL2-4, which is located at 10q21.1 and have five exons. LNCAROD is a newly identified lncRNA and its biological significance and related molecular mechanisms are largely unknown. Recently, LNCAROD has been revealed to promote head and neck squamous cell carcinoma (HNSCC) by forming a ternary complex with HSPA1A and YBX1[10].

In this study, we found that LNCAROD was upregulated in HCC tissues and cells, with higher LNCA ROD expression predicting poorer prognosis of patient survival. Overexpression of LNCAROD promotes malignant phenotypes and chemoresistance in vitro and in vivo. Mechanistically, it was found that LNCAROD upregulated PKM2 levels to enhance glycolysis metabolism in HCC through two relatively independent processes: SRSF3 triggered PKM switching from PKM1 to PKM2, and the other by sponging miR-145-5p to upregulate PKM2. Our findings increase the understanding of lncRNA-driven machinery in HCC tumorigenesis and chemoresistance and unveil the importance of LNCAROD in HCC progression, thereby contributing to the development of a promising prognostic indicator and therapeutic target for HCC patients.
Materials and methods

Chemicals and antibodies
Lipofectamine 2000 transfection reagents and total RNA extraction agent (TRIzol) were purchased from Invitrogen (Grand Island, NY, USA). Antibodies against PKM1, PKM2, fibronectin, and β-actin were obtained from Abcam (Cambridge, MA, USA), whereas those against E-cadherin, N-cadherin, and vimentin were from Cell Signaling Technology (Danvers, MA, USA). α-Catenin antibodies were purchased from Becton Dickinson. Unless otherwise stated, all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Patient samples
All studies involving human samples were reviewed and approved by the ethics committee of The First Affiliated Hospital of Guangxi Medical University, and written informed consent was obtained from all patients based on the Declaration of Helsinki. Tumor and adjacent non-tumor tissues were collected from patients with HCC (n = 92) at the First Affiliated Hospital of Guangxi Medical University. The clinicopathological characteristics examined included age, sex, tumor nodule number, etiology, serum AFP level, tumor stage, tumor size, tumor differentiation, and vascular invasion. Tumor classification and grade were determined based on the pTNM classification advocated by the International Union Against Cancer.

Cell lines and cell culture
HCC cell lines including SNU-423, SNU-182, Huh7, HepG2, and HCC-LM3 were obtained from Guangzhou Cellcook Biotech Co., Ltd. SM-MC-7721 was from Shanghai Saily Biotechnologies Co., Ltd. Cells were cultured in an appropriate medium containing 10% fetal bovine serum (LBS; Gibco) supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL) to minimize the chance of germ contamination in a humidified atmosphere containing 5% CO2/95% air at 37 ºC. Normal human hepatocyte line THLE-2 was from Zhejiang Meissen Cell Technology Co., Ltd. and cultured according to ATCC guidelines for culturing this cell line, which are available at: https://www.atcc.org/products/crl-2706. All cell lines were confirmed to be mycoplasma negative during the experiments. The hypoxia model was established using 1% O2/5% CO2/94% N2 or via the introduction of CoCl2, a hypoxic mimetic agent [14].

shRNA and siRNA transfection
Short hairpin RNAs (shRNAs) specifically targeting LNCAROD, serine-and arginine-rich splicing factor 3 (SRSF3), and PKM2, and the small interference RNA (siRNA) targeting Mettl3, IGFB2BP1, and HIF1α were all obtained from GenePharma (Shanghai, China). These shRNAs or siRNAs were transfected into HCC cells using Lipofectamine 2000. For in vivo experiments, sh-LNCAROD was delivered into HCC cells via lentiviral transfection.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA was extracted using an RNA simple Total RNA Kit (TIANGEN, DP419), whereas cytoplasmic and nuclear RNA was isolated using a Nuclear/Cytoplasmic Isolation Kit (BioVision, San Francisco, CA, USA) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized using a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, #K1622) and poly (A) polymerase reaction buffer (NEB, M0276s) according to the manufacturer’s instructions. RT-qPCR was performed using the iTaqTM Universal SYBR Green Supermix. The fold-change in RNA expression was quantified using the 2^-ΔΔCt method. The primer sequences used in this study are listed in Table S1.

LncRNA fluorescence in situ hybridization
LncRNA fluorescence in situ hybridization (FISH) was performed to determine the subcellular localization of LNCAROD. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature. After permeabilization in 0.5% Triton X-100 for 5 min, cells were treated with pre-hybridization buffer at 37 ºC for 30 min and then subjected to hybridization with the LNCAROD probe (RiboBio, Guangzhou, China) overnight at 37 ºC in the dark. Subsequently, the cells were washed in turn with 4×SSC containing 0.1% Tween 20 thrice, 2×SSC once, 1×SSC once at 37 ºC, and 1×PBS once at room temperature in the dark. Finally the nuclei were counterstained with DAPI for observation using a fluorescence microscope.

Immunohistochemistry (IHC)
IHC was performed on paraformaldehyde-fixed, paraffin-embedded tissue specimens using heat-mediated antigen retrieval citrate (0.01 M, pH 6.0). Endogenous peroxidase activity was blocked using 3% H2O2 for 15 min at room temperature (RT). Thereafter, the sections were incubated with goat serum for 1 h to block the non-specific binding sites and then with primary antibodies overnight at 4 ºC. After rinsing three times for 5 min each with PBS, the sections were further incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. Each section was then rinsed with PBS thrice for 5 min each, and the reactions were developed using diaminobenzidine tetrahydrochloride (DAB) as a substrate. Cellular nuclei were counterstained using hematoxylin, and the sections were sealed with neutral gum. Images were obtained using an
Olympus X71 inverted microscope (Olympus Corp., Tokyo, Japan).

**Measurement of extracellular acidification rate (ECAR)**
The glycolytic capacity of living cells was evaluated through ECAR measurement using Seahorse Bioscience XF96 Extracellular Flux Analyzer and software (Seahorse Bioscience, North Billerica, MA, USA). Briefly, 4 × 10^4 cells were seeded in a cell culture microplate XF96 in triplicate. ECAR readings were initially measured under basal conditions and further determined after the successive addition of glucose, oligomycin (an oxidative phosphorylation inhibitor), and 2-deoxy-D-glucose (2-DG, a glycolytic inhibitor) at the indicated time points using a Seahorse XF Glycolysis Stress Test Kit (Seahorse Bioscience) according to the manufacturer’s instructions.

**Methylated RNA immunoprecipitation qPCR (MeRIP-qPCR)**
The MeRIP-qPCR assay was performed to determine the level of LNCAROD m^6^A. Total intracellular RNA was extracted using TRIzol reagent. Anti-m^6^A antibodies or anti-immunoglobulin G (IgG; Cell Signaling Technology) (3 µg) was first conjugated to protein A/G magnetic beads and mixed with 100 µg aliquot of total RNA in L buffer containing RNase/protease inhibitors. m^6^A-modified RNA was eluted twice with 6.7 mM N^6^-methyladenosine 5'-monophosphate sodium salt at 4 °C for 1 h. Subsequently, RT-qPCR analysis was performed to determine the m^6^A enrichment on LNCAROD using the following primer sequences: F, 5'-GAATAGGTGGCCAGA; and R, 5'-CCGTTGTGGGCAGAAGTTGA-3'.

**Mouse xenograft model**
Four-week-old BALB/c nude mice were purchased from the Animal Center of Guangxi Medical University (Nanning, China). All animal experimental protocols were performed in accordance with the National Institutes of Health’s Animal Use Guidelines on the Use of Experimental Animals. HCC-LM3 cells with silenced LNCAROD or the negative control were subcutaneously injected into the flank region of the mice at 2 × 10^6^ cells. Tumor volume was measured weekly and calculated as follows: V = (length × width^2^)/2. After 4 weeks, the tumors were excised and weighed. To evaluate the extent of lung metastasis, 1 × 10^6^ control or LNCAROD knockdown HCC-LM3 cells were injected into nude mice via the tail vein of nude mice. On the 6th week of the mice, the wounds were sacrificed, and the lung tissues were harvested and fixed in 4% formaldehyde solution. The tumors were counted on the hematoxylin-eosin (H&E) stained lung tissues.

**RNA immunoprecipitation (RIP) assay**
A Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) was used according to the manufacturer’s instructions. Briefly, cell extracts were immunoprecipitated with sepharose beads conjugated antibodies against AGO2, IGF2BP1, SRSF3, or IgG at 4 °C for 6 h. To remove proteins from the complex, 0.1% SDS/Proteinase K (0.5 mg/ml, 30 min at 55 °C) was used. Immunoprecipitated proteins and RNAs were detected using western blot and RT-qPCR, respectively.

**RNA pull-down assay**
A Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific, 20164) was used according to the manufacturer’s instructions. In brief, cell lysates were treated with RNase A/Proteinase K and incubated with biotinylated LNCAROD in the presence of streptavidin magnetic beads which can capture the proteins/miRNAs potentially interacting with LNCAROD. A Pierce™ RNA 3'-End Debiotinylination Kit (Thermo, 20,163) was used for LNCAROD biotinylation labeling. Proteins and RNAs in the captured protein–RNA complex were analyzed using western blot and RT-qPCR, respectively.

**Statistical analysis**
Numerical data are presented as the mean ± standard deviation (SD) of at least three independent experiments. Student’s t-test or one-way analysis of variance (ANOVA) was used for comparison between groups. Qualitative data were analyzed using the chi-square test. Kaplan-Meier analysis was used for survival analysis with inter-group comparison performed using the log-rank test. Linear regression analysis was performed to evaluate the correlation between gene expression levels. Statistical analysis was conducted in the GraphPad Prism v8.0 (GraphPad, Inc., USA) and the Statistical Software Package for Social Sciences (v 22.0; SPSS, Inc., Chicago, IL, USA). Differences were considered statistically significant at P < 0.05.

**Results**
LNCAROD is highly expressed in HCC tissue and associated with a poor prognosis
Previously we performed a lncRNA microarray assay of 18 HCC and adjacent para-tumorous tissues and identified 26 significantly upregulated lncRNAs (all fold change > 6 and P < 0.01) [1], suggesting that these lncRNAs might play a critical role in HCC tumorigenesis. Among these upregulated lncRNAs, LNCAROD (ENST00000443523.1) was the fourth most upregulated gene. However, its role in HCC tumorigenesis is completely unclear and thus interested us. Here, we found a significant upregulation of LNCAROD in HCC tissues upon comparison with adjacent normal liver tissues.
across TCGA datasets, and this was verified by RT-qPCR assay results of matched HCC tumor and adjacent normal tissues (Fig. 1 A-B). The enhanced expression of LNCAROD was also observed in HCC cell lines (SNU-182, HepG2, Huh7, SNU-449, SMMC-7721, and HCC-LM3) compared to the normal THLE-2 liver cell line (Fig. 1 C). Further, as shown in Fig. 1D, Kaplan-Meier analysis showed that HCC patients with high level of LNCAROD had poorer prognosis ($P = 0.0039$). Correlation analysis with clinicopathological parameters demonstrated that high LNCAROD levels are associated with unfavorable tumor-node-metastasis (TNM) stage, tumor size, differentiation grade, and microvascular invasion (Table S2). Collectively, these findings strongly suggest that LNCAROD is highly expressed in HCC tissues, is positively associated with HCC malignancies, and might function as a chemoresistant molecule in HCC.

**LNCAROD promotes HCC cell growth, migration, invasion, and chemoresistance**

To identify the role of LNCAROD in HCC, HCC cell lines (SNU-449, HCC-LM3, SMMC-7721, and Huh7) were transfected with pcDNA3.1(+) vectors encoding human LNCAROD inserts or shRNAs, and transfection efficiency was verified by RT-qPCR (Figure S1A, B). To identify whether LNCAROD facilitates HCC cell growth, CCK8 and colony formation assays were performed. As shown in Fig. 2 A-B, LNCAROD silencing in SNU-449 and HCC-LM3 cell lines decreased cell proliferation compared with their control counterparts, whereas LNCAROD overexpression significantly enhanced their proliferation (Figure S2A-B), demonstrating that LNCAROD has a potent HCC-promoting effect.

Subsequently, we examined the migration and invasion properties of HCC cells with LNCAROD knockdown or overexpression. LNCAROD knockdown significantly decreased the migration and invasion of SNU-449 and HCC-LM3 cells (Fig. 2 C), whereas its overexpression significantly promoted migration and invasiveness of SMMC-7721 and Huh7 cells (Figure S2C). Epithelial-to-mesenchymal transition (EMT) is closely related to cancer cell migration and invasion. In line with this, we found that epithelial markers E-cadherin and $\alpha$-catenin were increased, whereas the mesenchymal markers N-cadherin, fibronectin, and vimentin were decreased in HCC cell lines upon LNCAROD knockdown (Fig. 2D); LNCAROD overexpression produced the opposite results (Figure S2D), indicating that EMT in HCC cells is positively regulated by LNCAROD. In summary, these findings suggest that LNCAROD accelerates HCC cell migration and invasiveness.

---

**Fig. 1** LNCAROD is highly expressed in HCC tissue and associated with a poor prognosis. **A** Gene expression of LNCAROD in human HCC compared with normal tissues from TCGA data sets. **B** LNCAROD expression in HCC tissues compared with paired adjacent normal tissues in HCC patients. **C** LNCAROD expression in HCC cell lines compared with THLE2 cells. **D** Kaplan-Meier analyses for the correlation between the LNCAROD level and overall survival in 92 HCC patients. The median was set as the cutoff point to differentiate high or low expression of LNCAROD. Data are shown as the mean ± SD. **$^{**}P < 0.01$
Fig. 2 (See legend on next page.)

A. 

B. 

C. 

D. 

E. 

F. 

G. 

H. 

I. 

J. 

K. 

Table: Number of mice with distant metastasis

| Group       | Number of mice with distant metastasis |
|-------------|----------------------------------------|
| shCtr       | 7/8                                    |
| shLNCAROD  | 4/8                                    |
| shCtr+5-FU | 5/8                                    |
| shLNCAROD+5-FU | 1/8                                |

L. 

Fig. 2 (See legend on next page.)
We further investigated the effect of LNCAROD on HCC chemoresistance to 5-fluorouracil (5-FU). Although this agent has greatly improved the prognosis of HCC patients, acquired or inherent chemoresistance compromises its overall efficacy in HCC treatment [15, 16]. As seen in Fig. 2E-F, LNCAROD knockdown sensitized HCC cells to 5-FU treatment, whereas its overexpression promoted 5-FU resistance in SMMC-7721 and Huh7 cells (Figure S2E-F). Besides, flow cytometry assay showed that LNCAROD knockdown notably facilitated 5-FU-induced HCC cell apoptosis (Fig. 2G).

Consistent with the in vitro findings above, LNCAROD deficiency evidently decreased tumor growth rate and ki67-positive cell number in both the normal saline (NS) and 5-FU-treated nude mice xenografts (Fig. 2A-D). In addition, in the lung metastasis model, we observed that LNCAROD knockdown significantly impaired the lung metastasis capacity of HCC cells as evidenced by the dramatic decrease in both the number of mice with lung tumors and that of tumors in mouse lungs treated with NS or 5-FU (Fig. 2E-F). Collectively, these results indicate that LNCAROD facilitates the malignancy of HCC cells, thereby rendering chemoresistance to 5-FU.

**Mettl3/IGF2BP1-mediated m6A modification is involved in LNCAROD upregulation.**

Subsequently, we explored the mechanism underlying the upregulation of LNCAROD in HCC cells. The m6A modification is emerging as a critical mechanism for the modulation of RNA life cycle, expression, and function [17]. Methyltransferase-like 3 (Mettl3) plays an important role in mediating m6A modification in mammalian cells, and its silencing led to the decreased expression of LNCAROD in HNSCC [10].

By searching the TCGA database, we found that Mettl3 levels were significantly higher in HCC tissues than in corresponding para-cancerous tissues (Fig. 3A). Many m6A sites were found with LNCAROD using the RMBase (http://rna.sysu.edu.cn/rmbase/index.php) prediction. Thus, we hypothesized that LNCAROD upregulation might be due to its m6A modification. m6A RNA IP (RIP) and RT-qPCR results showed that m6A was significantly more abundant in HCC cell lines (SNU-449 and HCC-LM3) than in normal THLE-2 liver cells (Fig. 3B). Furthermore, Mettl3 silencing significantly decreased LNCAROD level (Fig. 3C), whereas its overexpression increased it (Fig. 3D). RIP assays showed that Mettl3 depletion reduced the m6A modification of LNCAROD in HCC cells (fig. 3E). In the presence of actinomycin D, an agent that blocks the de novo synthesis of RNA, Mettl3 depletion decreased the stability of LNCAROD, whereas Mettl3 overexpression produced the opposite result (Fig. 3F). Collectively, these data suggest that Mettl3 acts as an m6A writer and plays a critical role in maintaining the high level of LNCAROD in HCC.

The insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a “reader” of m6A and is essential in many cancers as it maintains the stability of m6A-modified noncoding RNAs [18]. Here, we confirmed the direct binding between IGF2BP1 and LNCAROD using an RIP assay (Fig. 3G). IGF2BP1 silencing in HCC cells significantly decreased the LNCAROD level, whereas its overexpression increased it (Fig. 3H-I). In the presence of actinomycin D, LNCAROD stability was significantly impaired following IGF2BP1 silencing but was enhanced by IGF2BP1 overexpression (Fig. 3J). Furthermore, the interaction between IGF2BP1 and LNCAROD was remarkably interrupted upon Mettl3 depletion (Fig. 3K). Taken together, our data indicate that the m6A modification maintained by both the “writer” Mettl3 and the “reader” IGF2BP1 is pivotal in maintaining the stability and upregulation of LNCAROD in HCC cells.

**Enhanced glycolysis is critically implicated in LNCAROD-induced HCC malignancy.**

To explore the molecular mechanism by which LNCAROD triggers HCC malignancy and chemoresistance, we performed RNA-sequencing analysis (Fig. 4A). Using KEGG analysis, we found that the terms including vitamin B6 metabolism, type II diabetes, pyruvate metabolism, proteasome, and glycolysis/gluconeogenesis were significantly enriched in HCC cells with LNCAROD knockdown, of which glycolysis was the most significantly enriched (Fig. 4B). As shown in Fig. 4C, LNCAROD knockdown remarkably inhibited glucose consumption, lactate production, and ATP production. In contrast, dramatically increased glucose consumption,
lactate production, and ATP production were observed in LNCAROD-overexpressing HCC cells (Figure S3A-B). In addition, LNCAROD knockdown effectively decreased the extracellular acidification rate (ECAR). In contrast, ECAR was significantly increased upon LNCA-ROD overexpression (Fig. 4D and Figure S3C-D). These results indicate that LNCAROD increases glycolysis metabolism in HCC cells.

Fig. 3 Mettl3/IGF2BP1-mediated m6A modification is involved in the upregulation of LNCAROD. A Mettl3 expression in HCC was analyzed using the TCGA database. B RIP-RT-qPCR assay results show the enrichment of m6A-modified LNCAROD in SNU-449 and HCC-LM3 cells compared with THLE2 cells. C-D Effect of Mettl3 knockdown or overexpression on LNCAROD expression. E RIP-RT-qPCR results show the enrichment of m6A-modified LNCAROD following Mettl3 depletion. F LNCAROD stability analysis in HCC-LM3 cells with Mettl3 silencing or overexpression in the presence of actinomycin D. G RIP-RT-qPCR assay results show the enrichment of the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) on LNCAROD in HCC cells. H-I Effect of IGF2BP1 knockdown or overexpression on LNCAROD expression. J LNCAROD stability analysis in HCC-LM3 cells with IGF2BP1 silencing or overexpression in the presence of actinomycin D. K RIP-RT-qPCR assay results show the enrichment of IGF2BP1 on LNCAROD upon Mettl3 silencing. Data are shown as the mean ± SD. *P < 0.05; **P < 0.01
Enhanced glycolysis is critically implicated in LNCAROD-induced HCC malignant behaviors. A Heatmap showing the differentially expressed genes following LNCAROD knockdown. B KEGG analysis of the enriched pathways in HCC cells with LNCAROD knockdown. Effects of LNCAROD knockdown on (C) glucose consumption (top), lactate production (middle), and ATP production (bottom) and (D) extracellular acidification rate (ECAR) in SNU-449 and HCC-LM3 cells. Effect of 2-deoxy-D-glucose (2-DG) treatment on the (E) viability, (F) colony formation, (G) migration and invasion, and (H) EMT marker expression of HCC cells. I Effect of LNCAROD knockdown on the mRNA expression of PKM1, PKM2, and PFKL in HCC cells. Data are shown as the mean ± SD. * P < 0.05; ** P < 0.01.
We next determined whether glycolysis is implicated in LNCAROD-mediated promotion of HCC cell growth, migration, invasion and found that these processes were significantly inhibited by 2-deoxy-D-Glucose (2-DG), a glycolysis inhibitor (Fig. 4E-G). Moreover, 2-DG effectively reversed the LNCAROD-induced upregulation of N-cadherin, fibronectin, and vimentin, as well as the downregulation of E-cadherin and α-catenin (Fig. 4H). Taken together, these data suggest that LNCAROD induces HCC malignancies via increased cell glycolysis.

In addition, we examined the influence of LNCAROD on the expression of key glycolysis regulatory genes in HCC cells using RT-qPCR. As shown in Fig. 4I, LNCAROD knockdown significantly suppressed the expression of PKM2 and PFKL but did not affect that of PKM1. Other glycolysis regulatory genes, including GLUT3, HK-2, PDK1, and ENO1, were not significantly affected by LNCAROD (data not shown).

**LNCAROD localization contributes to PKM alternative splicing and increased tumor malignancy**

Thus far, our data showed that LNCAROD acts as an important oncogene in HCC progression. We next explored the mechanism underlying its HCC-promoting effect. First, we evaluated the subcellular localization of LNCAROD in SNU-449 and HCC-LM3 cells using RT-qPCR. As shown in Fig. 5A-B, LNCAROD was well-distributed in both the cytoplasm and the nucleus. As such, we hypothesized that LNCAROD exerts its HCC-promoting effect via both nuclear and cytoplasmic pathways.

LncRNAs can regulate the biological functions of specific nuclear proteins, and are critically involved in tumor progression via interacting with proteins. We predicted the potential LNCAROD–protein interactions using catRAPID (http://service.tartaglialab.com/page/catrapid_group). Bioinformatics analysis revealed that the serine- and arginine-rich splicing factor 3 (SRSF3), a splicing factor of PKM that induces PKM switching from PKM1 to PKM2, is a potential LNCAROD-interacting protein (Table S3). Furthermore, we observed that SRSF3 deficiency decreased PKM2 levels but increased those of PKM1 in HCC cells (Figure S4A-D).

Given these findings, we speculate that LNCAROD exerts its oncogenic role by directly binding to SRSF3 to promote PKM isoform switching from PKM1 to PKM2. This hypothesis is supported by previous studies reporting that PKM switching towards PKM2 plays an oncogenic role in various cancers [19–21]. Consistent with this, we found that higher PKM2 levels in HCC patients were significantly correlated with decreased OS patient survival (Figure S5). We performed a RIP assay and observed LNCAROD enrichment with SRSF3 in the interactome (Fig. 5C) that was further validated by the RNA pull-down assay results (Fig. 5D).

In addition, we identified the implication of SRSF3 in LNCAROD-mediated regulation of PKM alternative splicing and found that SRSF3 knockdown greatly alleviated LNCAROD-induced PKM switching (Fig. 5E-F). Furthermore, knockdown of SRSF3 in LNCAROD-overexpressed cells greatly blunted the increase of HCC cell proliferation, migration, invasion, and glycolysis (Fig. 5G-M).

We also explored the critical role of LNCAROD/SRSF3/PKM2 in HCC tumorigenesis. As shown in Figure S6A-B, LNCAROD or SRSF3 knockdown significantly inhibited HCC cell proliferation. The combination of shLNCAROD and shSRSF3 yielded a stronger inhibitory effect on HCC proliferation than their individual knockdown, whereas a stronger proliferation-promoting effect was observed for the combined overexpression of LNCAROD and SRSF3 (Figure S7A-B). Notably, the growth-suppressing effect of the combined LNCAROD/SRSF3 knockdown was significantly reversed by PKM2 overexpression (Figure S6A-B). In contrast, the growth-promoting effect of their combined overexpression was significantly alleviated by PKM2 knockdown (Figure S7A-B). The synergistic effects on HCC cell migration, invasion, and glycolysis were also observed between LNCAROD and SRSF3, which were also PKM2 dependent (Figure S6C-G and Figure S7C-G).

**miR-145-5p sponging activity decreases PKM2 level and is involved in the oncogenic roles of LNCAROD in HCC**

Considering the nuclear and cytoplasmic localization of LNCAROD, we hypothesized that the ceRNA mechanism might also contribute to the oncogenic effect of LNCAROD in HCC. To verify this assumption, we first predicted potential LNCAROD target miRNAs using the bioinformatics database The Encyclopedia of RNA Interactomes (ENCORI, previously known as starBase v2.0) [22] and randomly selected five miRNAs for subsequent experimental verification.

According to the results of the RNA pull-down assay, miR-145-5p was the most enriched among all other miRNA candidates in the precipitate of LNCAROD (Figure S8A-B). Furthermore, miR145-5p significantly decreased the luciferase activity of LNCAROD WT but did not affect that of LNCAROD MUT (Figure 6A). We also observed that miR-145-5p levels were downregulated in HCC cells upon the overexpression of LNCAROD (Fig. 6B). These findings indicate that LNCAROD targets and sequesters miR-145-5p to prevent RISC-mediated downstream mRNA silencing. Thus, we tested this hypothesis using RIP and RNA pull-down assays. LNCAROD and miR-145-5p were highly enriched in the Ago2 precipitate (Figure 6C). In agreement with this, higher
Fig. 5 Implication of SRSF3 in LNCAROD-mediated regulation of PKM alternative splicing and HCC malignancy. A FISH assay determining the location of LNCAROD in HCC cells. B RT-qPCR assay of the nuclear and cytoplasmic distribution of LNCAROD in HCC cell lines. C RIP-RT-qPCR assay showing the relative enrichment of LNCAROD in anti-IgG- or anti-SRSF3-specific immunoprecipitate. D RNA pull-down assay was used to detect the interaction between LNCAROD and SRSF3. E-F Effect of SRSF3 knockdown on the LNCAROD-mediated PKM1 and PKM2 alterations in SMMC-7721 and Huh7 cells at mRNA and protein levels. G Huh7 cell viability; H colony formation, migration and invasion; I glucose consumption; J lactate production; K ATP production; L and extracellular acidification rate (ECAR). Data are shown as the mean ± SD. *P < 0.05; **P < 0.01
Fig. 6 (See legend on next page.)
enrichments of miR-145-5p and Ago2 were observed in the biotin-labeled LNCAROD group than the control (Fig. 6D). These data suggest that LNCAROD acts as a molecular sponge for miR-145-5p in HCC via the ceRNA mechanism.

Then, we examined the role of miR-145-5p in HCC progression by screening for its potential targets and predicted a potential binding between PKM and miR-145-5p, indicating that PKM might be a direct target of miR-145-5p. To confirm this, dual-luciferase reporter assays were performed. We found that miR-145-5p significantly decreased the luciferase activity of PKM WT, but no significant inhibition of PKM MUT was detected (Fig. 6E). Furthermore, miR-145-5p significantly inhibited the expression of PKM1/2 (Fig. 6F-G). Subsequently, we analyzed the involvement of miR-145-5p in LNCAROD-mediated PKM2 alterations and HCC tumorigenesis. As seen in Fig. 6 H-I, the LNCAROD-induced PKM2 upregulation was significantly suppressed by miR-145-5p mimics. Collectively, these findings suggest that LNCAROD increases PKM2 levels through targeting miR-145-5p.

Furthermore, the oncogenic effects of LNCAROD in terms of cell proliferation, migration, invasion, and glycolysis were suppressed by the miR-145-5p mimic (Figure S9A-G), thereby suggesting an indispensable role of miR-145-5p in LNCAROD-mediated modulation of PKM2 and HCC tumor phenotypes. SRSF3 silencing did not affect miR-145-5p expression (data not shown), demonstrating that LNCAROD/SRSF3/PKM2 and LNCAROD/miR-145-5p/PKM2 exerted their oncogenic function in HCC in a relatively independent manner.

**LNCAROD plays a more important role in mediating HCC tumorigenesis under hypoxia than normoxia**

The hypoxia-inducible factor-1α (HIF-1α), a master cancer driver under hypoxic conditions, regulates aerobic glycolysis in many cancer types, including HCC in a PKM2-dependent manner [23]. Therefore, we compared the oncogenic efficiency of LNCAROD under hypoxic and normoxic conditions and found that its overexpression resulted in significantly higher proliferation of HCC cells under hypoxia than normoxia (Fig. 7 A-B). The combination of LNCAROD and hypoxic treatment synergistically enhanced tumor cell migration, invasion, and glycolysis (Fig. 7 C-G). A more noticeable increase in PKM2 expression was also observed following LNCAROD overexpression under hypoxic conditions (Fig. 7 H-I).

Subsequently, we determined the role of HIF1α in LNCAROD-mediated biological effects under hypoxia and observed that induction of PKM2 upregulation by LNCAROD was greatly attenuated by HIF1α knockdown (Figure S10A-B). Similarly, LNCAROD-promoted HCC cell proliferation, migration, invasion, and glycolysis under hypoxia were also remarkably inhibited by HIF1α knockdown (Figure S10C-I). Collectively, these results indicate that LNCAROD has a more potent oncogenic role in HCC under hypoxic conditions, probably via a HIF1α-dependent mechanism.

**Discussion**

Although LNCAROD has been previously reported to promote HNSSC progression by acting as a scaffold for the interaction between YBX1 and HSPA1A [10], the molecular function and mechanism of LNCAROD in HCC remain elusive. In this study, we revealed its oncogenic role in HCC tumor malignancy and chemoresistance. Overall, LNCAROD levels were upregulated in HCC tissue and were positively associated with HCC cell proliferation, migration, invasion, and chemoresistance to 5-FU. LNCAROD is distributed in both the nucleus and cytoplasm of HCC cells and promotes HCC progression via enhanced aerobic glycolysis through two independent routes: (1) interaction with SRSF3 to trigger PKM switching from PKM1 to PKM2 (nuclear LNCAROD) and (2) sponging miR-145-5p to upregulate PKM2 (cytoplasmic LNCAROD) via the ceRNA mechanism.

Accumulating evidence strongly suggests that IncRNAs play an essential role in the initiation and progression of malignant tumors, including HCC [12, 24, 25]. Here, we showed that LNCAROD is overexpressed in HCC tissues and cell lines compared with their respective adjacent non-cancerous tissues, which is consistent with previous reports showing that LNCAROD levels were higher in HNSSC and tongue squamous cell carcinoma (TSCC) [10, 26]. Data from clinical specimens showed that high levels of LNCAROD in HCC tissues are closely correlated with unfavorable
Fig. 7 (See legend on next page.)
we found that LNCAROD is localized both in the nucleus [10], contributing to the Warburg effect in HCC cells [32, 43]. As a transcription factor, HIF1α enhances glycolysis by promoting the transcription of glycolysis-related genes, including PKM2, which is a pivotal glycolytic regulator, and its high expression enhances glycolysis by increasing the PKM2/PKM1 ratio, glycolysis enhancement, and ultimately HCC malignancy.

Interestingly, we further revealed that PKM2 upregulation by LNCAROD was also dependent on the inhibition of miR-145-5p via the cytoplasmic ceRNA mechanism. Hence, we propose that LNCAROD exerts its oncogenic role in HCC by elevating PKM2 levels through a two-fold mechanism: (a) increasing PKM2 expression in the nucleus via SRSF3-mediated PKM alternative splicing and (b) maintaining PKM2 level in the cytoplasm by functioning as a ceRNA for miR-145-5p.

HCC cells are commonly exposed to a hypoxic microenvironment due to aberrant microvasculature and unrestrained tumor growth and expansion. HIF1α is commonly upregulated and is a well-established oncogenic factor in HCC, especially under hypoxia [14, 32]. It is a pivotal glycolytic regulator, and its high expression contributes to the Warburg effect in HCC cells [32, 43]. As a transcription factor, HIF1α enhances glycolysis by promoting the transcription of glycolysis-related genes.
including GLUT-1, HK-2, PFK1, PKM2, and PDK [32, 44]. Thus, we hypothesize that LNCAROD plays a stronger oncogenic role in HCC by increasing PKM2 levels under hypoxia than normoxia. Finally, we demonstrated that in comparison with normoxic conditions, LNCAROD overexpression exhibited increased malignancy-promoting effect under hypoxic conditions. The effect of LNCAROD on PKM2 was also more evident under hypoxia. Intriguingly, the influence of LNCAROD on HCC cell malignant phenotypes and PKM2 production under hypoxia was greatly blunted by HIF1α knockdown. Thus, LNCAROD is more implicated in hypoxia- or HIF1α-driven HCC malignancy than that driven by normoxia.

**Conclusion**

In summary, our study revealed the function of LNCAROD in promoting HCC glycolysis and tumor malignancy and its underlying mechanism. Mechanistically, the effects of LNCAROD in HCC originate from PKM2 upregulation. LNCAROD interacts with SRSF3 to induce PKM switching towards PKM2 and alleviates miR-145-5p inhibition on PKM2 level via the ceRNA mechanism (Fig. 8). Our findings contribute to a deepened understanding of LNCAROD in HCC tumor biology and the preferential use of aerobic glycolysis in cancer cells. LNCAROD might represent a promising diagnostic, prognostic, and therapeutic target for HCC.

**Abbreviations**

ATCC: American Type Culture Collection; CCK8: Cell counting kit 8; ceRNA: Competing endogenous RNAs; 5-FU: 5-fluorouracil; GO: Gene ontology; HCC: Hepatocellular carcinoma; HIF1α: Hypoxia inducible factor 1α; IGF2BP1: Insulin-like growth factor 2 mRNA-binding protein 1; lncRNAs: Long non-coding RNAs; Mettl3: Methyltransferase like 3; m 6A: N6-methyladenosine; OS: Overall survival; PKM: Pyruvate kinase; qRT-PCR: Quantitative real-time polymerase chain reaction; RIP: RNA binding protein immunoprecipitation; SRSF3: Serine and arginine rich splicing factor 3

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-02090-7.

**Additional file 1: Figure S1.** LNCAROD insertion or shRNA transfection efficiency as verified by RT-qPCR. (A) Determination of LNCAROD levels in SNU-449 and HCC-LM3 cells transfected with shCtr or shLNCAROD. (B) Determination of LNCAROD levels in SWMC-7721 and Huh7 cells transfected with the control vector or LNCAROD. Data are shown as the mean ± SD. **P < 0.01.

**Additional file 2: Figure S2.** LNCAROD overexpression promotes HCC malignancy. (A) CCK8, (B) colony formation, (C) migration and invasion, and (D) epithelial-to-mesenchymal transition markers expression assays in SWMC-7721 and Huh7 cells transfected with vector or LNCAROD. Data are shown as the mean ± SD. *P < 0.05; **P < 0.01.

**Additional file 3: Figure S3.** LNCAROD overexpression increases HCC glycolysis. Effect of LNCAROD overexpression on glucose consumption (left), lactate production (middle), and ATP production (right) in SWMC-7721 (A) and Huh7 (B) cells. Effect of LNCAROD overexpression on...
Acknowledgements

We would like to thank Editage (www.editage.cn) for English language editing.

Authors’ contributions

BT and YNF developed the original hypothesis and supervised the experimental design; GZJ, YW, and CJL performed in vitro and in vivo experiments; SHL, HLD, CJL, and ZQW detected the clinical specimens; LD, HZS, YJS, and NWZ analyzed the data and performed statistical analysis; GZJ and BT wrote and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (grant numbers 8171938, 82173118, 82072752, and 81772498), the Guangxi Science Fund for Distinguished Young Scholars Program (grant number 2016GXNSFDA380003), the Guangxi Medical University Training Program for Distinguished Young Scholars, the Guangxi Special Funds for Postdoctoral Projects, the 111 Project (grant number D17011), Key Programs of Science Foundation of Heilongjiang Province (ZD2019H002), Guangxi Natural Science Fund for Key Program of Research & Development (GuiKe AB21075003), and Guangxi Natural Science Fund for Guangdong-Guangxi United Program (2021GKNSFD0470504).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All participants provided written informed consent, and the study was approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University. The animal experiments protocols were in accordance with institutional guidelines approved by the Animal Care and Use Committee.

Consent for publication

All authors agree with the content of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, People’s Republic of China. 2Key Laboratory of Basic and Clinical Application Research for Hepatobiliary Diseases of Guangxi, 530021 Nanning, Guangxi, People’s Republic of China. 3Department of Pancreatic Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 300060 Tianjin, People’s Republic of China. 4Key Laboratory of Heilongjiang Province for Cancer Prevention and Control, School of Basic Medicine, Mudanjiang Medical University, 157011 Mudanjiang, People’s Republic of China.

Received: 25 May 2021 Accepted: 30 August 2021

References

1. Zhang Y, Tang B, Song J, Yu S, Li Y, Hu M, Zhou Y, Mei Y, Tan Y, Li X, Zeng Z, et al. Lnc-PDZD7 contributes to stromness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. J Exp Clin Cancer Res. 2019;38(1):92.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65(2):87–108.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61(2):69–90.
4. Wu L, Liu Y, Guo C, Shao Y. LncRNA OIP5-A51 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FoxD1/ERK pathway. Cancer Cell Int. 2020;20:296.
5. Yu H, Xu A, Wu B, Wang M, Chen Z. Long noncoding RNA NEAT1 promotes progression of glioma as a ceRNA by sponging miR-185-5p to stimulate DNMT1/mTOR signaling. J Cell Physiol. 2020;236:121–30.
6. Zhao X, Wang Y, He J, Deng R, Huang Q, Guo Y, Li L, Xie R, Yu J. LncRNA UCA1 maintains the low-tumorigenic and nonmetastatic status by stabilizing E-cadherin in primary prostate cancer cells. Mol Carcinog. 2020;59(10):1174–87.
7. Lin H, Zuo D, He J, Ji T, Wang J, Jiang T. Long noncoding RNA WEE2-A51 plays an oncogenic role in glioblastoma by functioning as a molecular sponge for microRNA-520d-3p. Oncol Res. 2020;28:591–603.
8. Sun L, Zhu W, Zhao P, Wang Q, Fan B, Zhu Y, Lu Y, Chen Q, Zhang J, Zhang F. Long noncoding RNA UCA1 from hypoxia-conditioned mHc-derived exosomes: a novel molecular target for cardioprotection through miR-873-5p/XIAP axis. Cell Death Dis. 2020;11(8):596.
9. Sun CC, Zhu W, Si J, Hu W, Zhang J, Zhuo Y, Zhang H, Wang J, Zhang Y, Huang SX, et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Med. 2020;12(1):77.
10. Ban Y, Tan P, Cai J, Li J, Hu M, Zhou Y, Mei Y, Tan Y, Li X, Zeng Z, et al. LncAROD is stabilized by m6A methylation and promotes cancer
progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020;14(6):1282–96.

11. Liu Z, Mo H, Sun L, Wang L, Chen Y, Yao B, Liu R, Niu Y, Tu K, Xu Q, et al. LncRNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/Akt/mTOR signaling pathway. Cancer Sci. 2020;111:115–28.

12. He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H, Zhu Z, Wang X, Jin S. Long noncoding RNA ZFPFM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):159.

13. Yamamoto T, Saitoh N. Non-coding RNAs and chromatin domains. Curr Opin Cell Biol. 2019;58:22–33.

14. Ling S, Shan Q, Zhan Q, Ye Q, Liu P, Xu S, He X, Ma J, Xiang J, Jiang G, et al. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a Hif1α/USP22 positive feedback loop upon TP53 inactivation. Gut. 2020;69(7):3322–34.

15. Wei I, Wang X, Lv L, Liu J, Xing H, Song Y, Xie M, Lei T, Zhang N, Yang M. The emerging role of micro-RNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18(1):147.

16. Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, Tang R, Cheng C, Chen L, Lin S, et al. MTF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo. Molecular mechanisms and therapeutic significance. Pharmacol Res. 2020;163:105265.

17. Zhang Y, Kang M, Zhang B, Meng F, Song J, Kaneko H, Shimamoto F, Tang M. m6A modification-mediated CBX8 induction regulates stemness and chemoresistance of colon cancer via upregulation of LGR5. Mol Cancer. 2019;18(1):185.

18. Yi YC, Chen XY, Zhang J, Zhu JS. Novel insights into the interplay between miRNA-modification and noncoding RNAs in cancer. Mol Cancer. 2020;19(1):121.

19. Zhao J, Li J, Hassan W, Xu D, Wang X, Huang Z. Sam68 promotes aerobic glycolysis in colorectal cancer by regulating PKM2 alternative splicing. Cancer Transl Med. 2020;7(4):1459.

20. Calabretta S, Belli P, Rebecchi I, Pizzo S, Franchini V, Careccia G, Sanei K, et al. Modulation of RNA alternative splicing by PTBP1 promotes gastric carcinoma progression in pancreatic cancer cells. Oncogene. 2016;35(1):208–19.

21. Sugiyama T, Taniguchi K, Matsuhashi N, Tajirika T, Futamura M, Takai T, Akao T. miR-133b inhibits growth of human gastric cancer cells by inducing apoptosis and cell cycle arrest through targeting PLAG1. Sci Transl Med. 2020;12(48):48.

22. Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD, Sette M. Long non-coding RNA ZFPM2-AS1 acts as a miRNA sponge and regulates cell proliferation and apoptosis in triple-negative breast tumor growth and metastasis through GLUT12–α-mannosidase 2 interaction with EZH2. J Exp Clin Cancer Res. 2020;39(1):229.

23. Wang Q, Lu D, Fan L, Wang Y, Xing H, Wang H, Liu J, Sun G. COX-2 induces angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):33.

24. Stielo L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2020;21(6):365–78.

25. Chen XJ, An N. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 methylation through binding to EZH2. J Cell Mol Med. 2020;25:37–46.

26. Han H, Wang S, Meng J, Lyu G, Ding G, Hao X, Wang L, Wang L, Lv Y, et al. Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of BOG via the P38-mediated recruitment of EZH2. Oncogene. 2019;38(1):1–13.

27. Song S, He X, Wang J, Song H, Jia Y, Zhou Z, Yu Z, Mao D, Xue Y. A novel long noncoding RNA, TMEM92–miR-687 promotes gastric cancer progression by binding to miR-687 to mediate CCL5. Mol Oncol. 2020;15:1256–73.

28. Lan Z, Yao X, Sun L, Liu J, Wang X. The Interaction Between IncRNA SNHG6 and HIF1A contributes to the Growth of Colorectal Cancer by Enhancing Aerobic Glycolysis through the Regulation of Alternative Splicing of PKM. Front Oncol. 2020;10:363.

29. Zhou J, Long D, Lin J, Wang Y, Li M, Wang L, Ding H, Li P. Emerging Roles of SR54–USP22 in Cancer. Front Oncol. 2020;10:577636.

30. Sen S, Lalwani P, Lummaa L, Webster NJ. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology. 2015;61(1):171–83.

31. Wang H, Lekbab F, Barnes N, Augustin J, Attoun T, Schnuriger A, Cassard AM, Pasayuk G, Perlemuter G, Bieche I, et al. Alteration of splicing factors’ expression during liver disease progression: impact on hepatocellular carcinoma outcome. Hepatol Int. 2019;13(4):454–67.

32. Chen H, Gao F, He M, Ding XF, Wang AM, Sze SC, Yu AC, Sun T, Chan AW, Wang X, et al. Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Cancer and Tumor-Specific Isoforms. Hepatology. 2019;70(3):1011–25.

33. Yao L, Yuan J, Zhang H, Yang B, Ma X, Wang T, Meng T, Sun W, Wei H, Ma X, et al. Reciprocal REG1–USP22 positive feedback loop upon TP53 inactivation. Gut. 2020;69(7):75.

34. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2020;21(6):365–78.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more from biomedcentral.com/submissions